Cannabigerol potentiates rivoceranib in hepatocellular carcinoma through a receptor-independent ER stress–calcium program that collapses the E2F1–FOXM1 axis
This study demonstrates that the non-psychoactive cannabinoid cannabigerol (CBG) synergizes with the VEGFR2 inhibitor rivoceranib to induce hepatocellular carcinoma cell death via a receptor-independent mechanism involving ER stress-driven calcium overload that collapses the E2F1–FOXM1 axis, thereby converting rivoceranib into a tumor-cell-intrinsic therapy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Liver cancer, specifically a type called hepatocellular carcinoma, remains one of the most difficult cancers to treat. While doctors have powerful drugs that can slow the disease by cutting off its blood supply, these treatments often stop working over time or fail to kill the cancer cells directly. The challenge lies in finding a way to make existing medicines work better without adding new side effects. To understand how researchers are tackling this, one must first grasp a few basic concepts about how cells function. Inside every living cell, there is a complex system of internal storage tanks that hold calcium, a mineral that acts as a critical signal for the cell's life and death. When a cell is healthy, it keeps calcium levels tightly controlled. However, if too much calcium floods the cell's interior, it can overwhelm the cell's defenses and trigger a self-destruct mechanism known as apoptosis. Scientists have long known that forcing this calcium overload is a potential way to kill cancer cells, but finding a safe and effective method to do so has been difficult.
A team of researchers set out to solve this puzzle by testing a new combination of two substances: rivoceranib, an existing drug used to treat advanced liver cancer, and cannabigerol, a non-psychoactive compound found in the cannabis plant. Rivoceranib is designed to block a specific protein that helps tumors build new blood vessels, but the researchers noticed it also seemed to have a weaker, direct effect on the cancer cells themselves that they could not fully explain. They suspected that if they could pair rivoceranib with a substance that stressed the cell's internal calcium systems, the two might work together to kill the tumor more effectively. To test this, they screened a variety of plant-based compounds and found that cannabigerol was the most powerful partner for rivoceranib. When they mixed the two drugs in a lab dish containing liver cancer cells, the combination was far more deadly than either drug used alone. The cells did not just stop growing; they began to die in large numbers.
The researchers then moved to living mice with liver tumors to see if this effect held up in a more complex environment. They treated the animals with rivoceranib, cannabigerol, or the combination of both. The results were clear: the mice receiving the drug pair saw their tumors shrink significantly more than those receiving just one of the drugs. The tumors in the combination group showed clear signs of cell death, while the single-drug groups showed much less effect. This confirmed that the two substances were working together to create a powerful anti-cancer response that neither could achieve on its own.
However, the most surprising part of the discovery was how this combination actually worked. Before starting, the scientists had a strong hunch about the mechanism. Because cannabigerol is known to interact with specific channels on the surface of cells that let calcium in, they expected the drug pair to work by opening these surface doors and flooding the cell with calcium from the outside. They even ran computer simulations that suggested rivoceranib might fit into these same surface channels. But when they tested this idea in the lab, the evidence pointed in a completely different direction. They found that blocking these surface channels did not stop the drugs from working. The cancer cells still died, and the calcium levels still rose, even when the surface doors were locked. This ruled out the idea that the drugs were working by opening surface gates.
Instead, the researchers discovered that the drugs were attacking the cell from the inside out. The combination triggered a state of severe stress within the cell's internal storage system, known as the endoplasmic reticulum. This stress caused the internal tanks to rupture and release their stored calcium into the main part of the cell. It was this internal flood, not an external one, that overwhelmed the cancer cells. The stress was so intense that it activated a specific protein called CHOP, which acts as a switch for cell death. Once this switch was flipped, the calcium surge disabled the cell's ability to divide and grow. The drugs effectively shut down the cell's internal machinery that controls the cell cycle, specifically by silencing a master regulator called FOXM1. Without this regulator, the cancer cells could not complete their division process and were forced into a state of arrest before eventually dying.
The study also clarified why this approach is unique. The researchers showed that the drugs did not rely on the cell's surface receptors to send the signal. Instead, they forced the cell to generate its own lethal stress response. By combining a drug that stresses the cell's internal environment with a plant compound that amplifies that stress, they created a chain reaction that collapsed the cancer cell's ability to survive. The findings suggest that this specific pairing of rivoceranib and cannabigerol could offer a new way to treat liver cancer by exploiting the cell's own internal weaknesses. While the research is currently at the stage of laboratory and animal studies, it provides a clear roadmap for how these two substances interact, moving beyond simple guesses about how they might work to a detailed understanding of the internal stress and calcium signals that drive the cancer cell to its end.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.